Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Body Dysmorphic Disorder
Interventions
DRUG

Levetiracetam

The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.

Trial Locations (1)

02903

Rhode Island Hospital Body Dysmorphic Disorder Program, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Butler Hospital

OTHER